

Announcement No. 20/2008

To OMX Nordic Exchange Copenhagen and the press.

Copenhagen, 8 April 2008

Exiqon A/S increases its share capital in connection with exercise of warrants

Exiqon A/S has today 8 April 2008 completed an increase of its share capital by DKK 148,135, nominal value, as a result of an exercise of warrants. The increase of the share capital is expected to be registered with the Danish Commerce and Companies Agency today 8 April 2008. The registered share capital subsequently amounts to DKK 30,139,473, nominal value, divided into 30,139,473 shares of DKK 1.00, nominal value, each.

The new shares are in accordance with the terms of the warrants exercised subscribed for without any preemption rights for the existing shareholders of the company, and the subscription price was DKK 9.50 per share of DKK 1.00, nominal value, each.

The new shares shall carry a right to any dividend for the financial year 2008 from the time of registration of the capital increase.

Following this exercise the number of outstanding warrants is 2,894,749.

For additional information please contact

CEO Lars Kongsbak, tel. +45 4566 0888 or +45 4090 2101

CFO, Hans Henrik Chrois Christensen tel.+45 4565 0953 or +45 4090 2131

About Exiqon

Exiqon's corporate mission is to combine leading-edge scientific expertise in gene expression with our proprietary LNA™ technology. Exiqon's products, services and scientific staff enable life science researchers to make groundbreaking discoveries. Moreover, Exiqon is addressing the unmet need for a new approach to the diagnosis of cancer. Exiqon's products are based on patented technology (LNA™ or Locked Nucleic Acids) that facilitates very precise and sensitive analysis of nucleic acids. Exiqon aims to expand the existing product offering for research use as well as to develop new proprietary molecular diagnostic products. Exiqon, through a number of recent initiatives, has positioned itself as a significant player in applying miRNA as the key biomarker in cancer diagnostics.

Disclaimer

Forward-looking statements: This announcement contains forward-looking statements regarding Exiqon's potential future development and financial performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of Exiqon's knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon's operations are characterized by the fact that its actual results may deviate significantly from that described herein as anticipated, believed, estimated or expected.